Still, if other obesity medications have a similar effect on heart attack risk, they could pursue the same FDA approval and Medicare coverage down the line
This comprehensive approach aligns with the American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline, which recommends pharmacotherapy alongside intensive health behavior and lifestyle treatment for adolescents with obesity
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al: Circulating angiogenic factors and the risk of preeclampsia
A vital advantage of the N-to-B route is reducing plasma exposure, decreasing peripheral side effects, and avoiding hepatic first-pass metabolism and the destructive effects of gastric acid